Dr. Stephen Barta is a physician scientist who focuses on hematological malignancies, especially lymphoid malignancies. Dr. Barta underwent intensive training in clinical and translational oncology research during the prestigious AACR/ASCO sponsored workshop for Methods in Clinical Research.

Dr. Barta currently directs the T-cell lymphoma program at the University of Pennsylvanian and serves as the Executive Officer of the NCI-sponsored AIDS Malignancy Consortium Lymphoma Working group, where he is also a member of the Executive Committee. In addition, he is a contributing member of the ECOG Lymphoma core committee and represent ECOG at the NCI T-cell lymphoma Working Group. Dr. Barta has authored or co-authored over 50 publications, with a focus on clinical research in T-Cell lymphomas and HIV-associated lymphomas. Some of Dr. Barta and team’s research findings include the demonstration that concurrent therapy with an antiviral integrase inhibitor would be well-tolerated and limit virus replication, clarification of the beneficial role of the monoclonal CD20-antibody rituximab and concurrent combination antiretroviral therapy in the treatment of HIV-associated NHL, and defining the role of autologous transplant in the management of young patients with mantle cell lymphoma.

Dr. Barta received his M.D from JWG University in Frankfurt, Germany and, after completing his clinical training in Hematology and Oncology in the United States, successfully completed the Albert-Einstein College of Medicine Clinical Research Training Program by obtaining a Master’s degree in “Clinical Research Methodology”.